Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSánchez Montalvá, Adrián
dc.contributor.authorBarios Profitós, Marta
dc.contributor.authorSalvador Velez, Fernando M
dc.contributor.authorVillar Gomez, Ana
dc.contributor.authorTórtola Fernández, Mª Teresa
dc.contributor.authorMolina Morant, Daniel
dc.contributor.authorLorenzo Bosquet, Carles
dc.contributor.authorEspinosa Pereiro, Juan
dc.contributor.authorMolina Romero, Israel
dc.date.accessioned2020-03-06T11:22:11Z
dc.date.available2020-03-06T11:22:11Z
dc.date.issued2019-08-27
dc.identifier.citationSánchez-Montalvá A, Barios M, Salvador F, Villar A, Tórtola T, Molina-Morant D, et al. Usefulness of FDG PET/CT in the management of tuberculosis. PLoS One. 2019 Aug 27;14(8):e0221516.
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11351/4707
dc.descriptionTuberculosis; Positron emission tomography (PET); FDG
dc.description.abstractBACKGROUND: The aim of our study is to describe the FDG-PET/CT findings in patients with tuberculosis and to correlate them with the patient's prognosis. METHODS: We retrospectively collected data from patients with tuberculosis, who had an FDG-PET/CT performed prior to treatment initiation from 2010 to 2015. RESULTS: Forty-seven out of 504 patients with active tuberculosis diagnosis (9.33%) underwent an FDG-PET/CT. The reasons for performing the FDG-PET/CT were: characterization of a pulmonary nodule (24; 51.1%), study of fever of unknown origin (12; 25.5%), study of lymph node enlargement (5; 10.6%) and others (6; 12.8%). Median age was 64 (IQR 50-74) years and 31 (66%) patients were male. Twenty-six (55.3%) patients had an immunosuppressant condition. According to the FDG-PET/CT, 48.6% of the patients had more than 1 organ affected and 46.8% had lymph node involvement. Median SUVmax of the main lesion was 5 (IQR 0.28-11.85). We found an association between the FDG accumulation and the size of the main lesion with a correlation coefficient of 0.54 (p<0.002). Patients with an unsuccessful outcome had a higher ratio SUVmax main lesion / SUVmean liver (1.92 vs 7.67, p<0.02). CONCLUSIONS: In our cohort, almost half of the patients had more than 1 organ affected and 46.8% of them had lymph node involvement. FDG uptake was associated with the size of the main lesion and seems to be related to the treatment outcome. The extent of its potential to be used as an early predictor of treatment success still needs to be defined.
dc.language.isoeng
dc.publisherPublic Library Science
dc.relation.ispartofseriesPLoS ONE;14(8)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTuberculosi
dc.subjectTomografia per emissió de positrons
dc.subjectRadiofàrmacs
dc.subject.meshPositron Emission Tomography Computed Tomography
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshTuberculosis
dc.titleUsefulness of FDG PET/CT in the management of tuberculosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1371/journal.pone.0221516
dc.subject.decstuberculosis
dc.subject.decstomografía por emisión de positrones
dc.subject.decsfluorodesoxiglucosa F18
dc.relation.publishversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221516
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Sánchez-Montalvá A, Salvador F, Espinosa-Pereiro J] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Programa de salut internacional de l'Institut Català de la Salut (PROSICS), ICS, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Grupo de Estudio de micobacterias (GEIM), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Madrid, Spain. [Barios M, Lorenzo-Bosquet C] Servei de Medicina Nuclear, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Villar A] Servei de Pneumologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Tórtola T] Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Programa de salut internacional de l'Institut Català de la Salut (PROSICS), ICS, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Molina-Morant D, Molina I] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Programa de salut internacional de l'Institut Català de la Salut (PROSICS), ICS, Barcelona, Spain
dc.identifier.pmid31454368
dc.identifier.wos000485049000023
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record